Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib
-
- Sekiguchi Yasunobu
- Department of Hematology, Saitama Cancer Center, Japan
-
- Nishimura You
- Department of Pathology, Saitama Cancer Center, Japan
-
- Kanda Hiroaki
- Department of Pathology, Saitama Cancer Center, Japan
-
- Kawamura Machiko
- Department of Clinical Laboratory Medicine, Saitama Cancer Center, Japan
-
- Kobayashi Kazuhiko
- Department of Clinical Laboratory Medicine, Saitama Cancer Center, Japan
-
- Kobayashi Hirofumi
- Department of Hematology, Saitama Cancer Center, Japan
Search this article
Description
<p>A 74-year-old woman was diagnosed with Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) in X-18. Fludarabine plus rituximab (FR) was started, and she showed remission. In July X-7, the serum creatinine (Cr) level increased to 1.67 mg/dL, and bendamustine plus rituximab (BR) was started. By November X-7, the Cr level had increased to 8.41 mg/dL, so she was started on hemodialysis (HD). In September X-1, she developed nephrotic syndrome. She was started on tirabrutinib at 480 mg. In July X, her nephrotic syndrome had improved, and a complete response (CR) was achieved. This is the first case of the administration of tirabrutinib in a patient undergoing HD. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 61 (16), 2503-2508, 2022-08-15
The Japanese Society of Internal Medicine
